Patents by Inventor Justin K. Murray
Justin K. Murray has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240084301Abstract: The present application relates to compositions and methods for modulating expression of Family with Sequence Similarity 13 Member A (FAM13A) protein. In particular, the present application relates to nucleic acid-based therapeutics for reducing FAM13A gene expression via RNA interference and methods of using such nucleic acid-based therapeutics to reduce abdominal adiposity, reduce body weight, reduce fat mass, improve metabolic parameters including insulin resistance and non-alcoholic steatohepatitis (NASH), and reduce risk of myocardial infarction.Type: ApplicationFiled: July 24, 2023Publication date: March 14, 2024Applicant: AMGEN INC.Inventors: Elizabeth Ann KILLION, Jerry Ryan HOLDER, Bryan MEADE, Justin K. MURRAY, Oliver R. HOMANN, Briana Renee GRIEGO, Murielle Marie VENIANT ELLISON
-
Publication number: 20230279399Abstract: The present invention relates to RNAi constructs for reducing expression of the HSD17B13 gene. Methods of using such RNAi constructs to treat or prevent liver disease, nonalcoholic fatty liver disease (NAFLD) are also described.Type: ApplicationFiled: June 3, 2021Publication date: September 7, 2023Applicant: Amgen Inc.Inventors: Daniel C. H. LIN, Michael OLLMANN, Justin K. MURRAY, Bradley J. HERBERICH, Amrita DAS, Patrick COLLINS, Oliver HOMANN
-
Patent number: 11732266Abstract: The present invention relates to RNAi constructs for reducing expression of the ASGR1 gene. Methods of using such RNAi constructs to treat or prevent cardiovascular disease, such as coronary artery disease and myocardial infarction, and to reduce serum non-HDL cholesterol levels are also described.Type: GrantFiled: October 26, 2020Date of Patent: August 22, 2023Assignee: AMGEN INC.Inventors: Michael Ollmann, Yang Li, Jun Zhang, Oliver Homann, Leslie P. Miranda, Justin K. Murray, Bin Wu, Oh Kyu Yoon, John Gordon Allen, Chawita Netirojjanakul, Yuan Cheng
-
Publication number: 20220307022Abstract: The present invention relates to RNAi constructs for reducing expression of the SCAP gene. Methods of using such RNAi constructs to treat or prevent liver disease, nonalcoholic fatty liver disease (NAFLD) are also described.Type: ApplicationFiled: June 1, 2020Publication date: September 29, 2022Applicant: AMGEN INC.Inventors: Amrita DAS, Bradley J. HERBERICH, Justin K. MURRAY, Oliver HOMANN, Michael OLLMANN, Daniel C.H. LIN
-
Publication number: 20220047621Abstract: The present invention relates to RNAi constructs for reducing expression of the MARC1 gene. Methods of using such RNAi constructs to treat or prevent liver fibrosis and fatty liver diseases, such as nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, are also described.Type: ApplicationFiled: August 12, 2021Publication date: February 17, 2022Applicant: AMGEN INC.Inventors: Justin K. MURRAY, Jun ZHANG, Oliver HOMANN, Jason C. LONG, Bryan MEADE
-
Publication number: 20220049252Abstract: The present invention relates to chemically-modified RNAi constructs for reducing expression of a target gene. In particular, the invention relates to specific patterns of modified nucleotides to be incorporated into RNAi constructs to improve in vivo stability and efficacy. Also described are pharmaceutical compositions comprising the chemically-modified RNAi constructs and methods of inhibiting target gene expression in vivo by administering the chemically-modified RNAi constructs, for example, to treat or ameliorate various disease conditions.Type: ApplicationFiled: December 9, 2019Publication date: February 17, 2022Applicant: AMGEN INC.Inventors: Justin K. MURRAY, Bin WU, Yuan CHENG, Bradley J. HERBERICH
-
Publication number: 20220017906Abstract: The present invention relates to RNAi constructs for reducing expression of the PNPLA3 gene. Methods of using such RNAi constructs to treat or prevent liver disease, nonalcoholic fatty liver disease (NAFLD) are also described.Type: ApplicationFiled: December 10, 2019Publication date: January 20, 2022Applicant: Amgen Inc.Inventors: Ingrid RULIFSON, Justin K. MURRAY, Michael OLLMANN, Oliver HOMANN
-
Publication number: 20210139912Abstract: The present invention relates to RNAi constructs for reducing expression of the PNPLA3 gene. Methods of using such RNAi constructs to treat or prevent liver disease, nonalcoholic fatty liver disease (NAFLD) are also described.Type: ApplicationFiled: December 12, 2018Publication date: May 13, 2021Applicant: AMGEN INC.Inventors: Ingrid RULIFSON, Justin K. MURRAY, Michael OLLMANN, Oliver HOMANN
-
Publication number: 20210108212Abstract: The present invention relates to RNAi constructs for reducing expression of the ASGR1 gene. Methods of using such RNAi constructs to treat or prevent cardiovascular disease, such as coronary artery disease and myocardial infarction, and to reduce serum non-HDL cholesterol levels are also described.Type: ApplicationFiled: October 26, 2020Publication date: April 15, 2021Applicant: AMGEN INC.Inventors: Michael OLLMANN, Yang LI, Jun ZHANG, Kaustav BISWAS, Oliver HOMANN, Leslie P. MIRANDA, Justin K. MURRAY, Bin WU, Oh Kyu YOON, John Gordon ALLEN, Chawita NETIROJJANAKUL, Yuan CHENG
-
Patent number: 10870856Abstract: The present invention relates to RNAi constructs for reducing expression of the ASGR1 gene. Methods of using such RNAi constructs to treat or prevent cardiovascular disease, such as coronary artery disease and myocardial infarction, and to reduce serum non-HDL cholesterol levels are also described.Type: GrantFiled: August 25, 2017Date of Patent: December 22, 2020Assignee: AMGEN INC.Inventors: Michael Ollmann, Yang Li, Jun Zhang, Oliver Homann, Leslie P. Miranda, Justin K. Murray, Bin Wu, Oh Kyu Yoon, John Gordon Allen, Chawita Netirojjanakul
-
Publication number: 20190309306Abstract: The present invention relates to RNAi constructs for reducing expression of the ASGR1 gene. Methods of using such RNAi constructs to treat or prevent cardiovascular disease, such as coronary artery disease and myocardial infarction, and to reduce serum non-HDL cholesterol levels are also described.Type: ApplicationFiled: August 25, 2017Publication date: October 10, 2019Applicant: AMGEN INC.Inventors: Michael OLLMANN, Yang LI, Jun ZHANG, Kaustav BISWAS, Oliver HOMANN, Leslie P. MIRANDA, Justin K. MURRAY, Bin WU, Oh Kyu YOON, John Gordon ALLEN, Chawita NETIROJJANAKUL, Yuan CHENG
-
Patent number: 10344060Abstract: Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted NaV1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of NaV1.7. Other embodiments are conjugated embodiments of the inventive composition of matter and pharmaceutical compositions containing the inventive composition of matter. Isolated nucleic acids encoding some embodiments of inventive polypeptides and expression vectors, and recombinant host cells containing them are disclosed. A method of treating or preventing pain is also disclosed.Type: GrantFiled: March 12, 2014Date of Patent: July 9, 2019Assignee: AMGEN INC.Inventors: Justin K. Murray, Jerry Ryan Holder, Malgorzata Wanska, Christopher M. Tegley, James R. Falsey, Elizabeth M. Doherty, Leslie P. Miranda, Kaustav Biswas, Bin Wu, Kelvin Sham, Jason C. Long
-
Patent number: 9796766Abstract: Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted NaV1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of NaV1.7 and/or NaV1.3. Other embodiments are conjugated embodiments of the inventive composition of matter and pharmaceutical compositions containing the inventive composition of matter. Isolated nucleic acids encoding some embodiments of inventive polypeptides and expression vectors, and recombinant host cells containing them are disclosed. A method of treating or preventing pain is also disclosed.Type: GrantFiled: April 20, 2016Date of Patent: October 24, 2017Assignee: AMGEN INC.Inventors: Justin K. Murray, Leslie P. Miranda, Stefan I. McDonough
-
Patent number: 9636418Abstract: Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted NaV1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of NaV1.7. Other embodiments are conjugated embodiments of the inventive composition of matter and pharmaceutical compositions containing the inventive composition of matter. Isolated nucleic acids encoding some embodiments of inventive polypeptides and expression vectors, and recombinant host cells containing them are disclosed. A method of treating or preventing pain is also disclosed.Type: GrantFiled: March 12, 2014Date of Patent: May 2, 2017Assignee: AMGEN INC.Inventors: Justin K. Murray, Jerry Ryan Holder, Malgorzata Wanska, Christopher M. Tegley, James R. Falsey, Elizabeth M. Doherty, Leslie P. Miranda
-
Publication number: 20160304570Abstract: Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted NaV1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of NaV1.7 and/or NaV1.3. Other embodiments are conjugated embodiments of the inventive composition of matter and pharmaceutical compositions containing the inventive composition of matter. Isolated nucleic acids encoding some embodiments of inventive polypeptides and expression vectors, and recombinant host cells containing them are disclosed. A method of treating or preventing pain is also disclosed.Type: ApplicationFiled: April 20, 2016Publication date: October 20, 2016Applicant: AMGEN INC.Inventors: Justin K. MURRAY, Leslie P. MIRANDA, Stefan I. MCDONOUGH
-
Patent number: 9340590Abstract: Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted Nav1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of Nav1.7 and/or Nav1.3. Other embodiments are conjugated embodiments of the inventive composition of matter and pharmaceutical compositions containing the inventive composition of matter. Isolated nucleic acids encoding some embodiments of inventive polypeptides and expression vectors, and recombinant host cells containing them are disclosed. A method of treating or preventing pain is also disclosed.Type: GrantFiled: March 16, 2012Date of Patent: May 17, 2016Assignee: AMGEN INC.Inventors: Justin K. Murray, Leslie P. Miranda, Stefan I. McDonough
-
Publication number: 20160024159Abstract: Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted NaV1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of NaV1.7. Other embodiments are conjugated embodiments of the inventive composition of matter and pharmaceutical compositions containing the inventive composition of matter. Isolated nucleic acids encoding some embodiments of inventive polypeptides and expression vectors, and recombinant host cells containing them are disclosed. A method of treating or preventing pain is also disclosed.Type: ApplicationFiled: March 12, 2014Publication date: January 28, 2016Applicant: AMGEN INC.Inventors: Justin K. MURRAY, Jerry Ryan HOLDER, Malgorzata WANSKA, Christopher M. TEGLEY, James R. FALSEY, Elizabeth M. DOHERTY, Leslie P. MIRANDA, Kaustav BISWAS, Bin WU, Kelvin SHAM, Jason C. LONG
-
Publication number: 20150023988Abstract: Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted Nav1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of Nav1.7. Other embodiments are conjugated embodiments of the inventive composition of matter and pharmaceutical compositions containing the inventive composition of matter. Isolated nucleic acids encoding some embodiments of inventive polypeptides and expression vectors, and recombinant host cells containing them are disclosed. A method of treating or preventing pain is also disclosed.Type: ApplicationFiled: March 12, 2014Publication date: January 22, 2015Applicant: AMGEN INC.Inventors: Justin K. MURRAY, Jerry Ryan HOLDER, Malgorzata WANSKA, Christopher M. TEGLEY, James R. FALSEY, Elizabeth M. DOHERTY, Leslie P. MIRANDA
-
Publication number: 20140073577Abstract: Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted Nav1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of Nav1.7 and/or Nav1.3. Other embodiments are conjugated embodiments of the inventive composition of matter and pharmaceutical compositions containing the inventive composition of matter. Isolated nucleic acids encoding some embodiments of inventive polypeptides and expression vectors, and recombinant host cells containing them are disclosed. A method of treating or preventing pain is also disclosed.Type: ApplicationFiled: March 16, 2012Publication date: March 13, 2014Applicant: AMGEN INC.Inventors: Justin K. Murray, Leslie P. Miranda, Stefan I. McDonough
-
Publication number: 20120121591Abstract: Disclosed are compositions of matter having an amino acid sequence of SEQ ID NO:4, or a pharmaceutically acceptable salt thereof, including embodiments comprising a toxin peptide analog related to ShK, HmK, and AETX-K and pharmaceutical compositions or medicaments containing them along with a pharmaceutically acceptable carrier. Some embodiments include a half-life extending moiety. Also disclosed are a method of preventing or mitigating a relapse of a symptom of multiple sclerosis and a method of treating an autoimmune disorder using the compositions.Type: ApplicationFiled: March 19, 2010Publication date: May 17, 2012Applicant: Amgen Inc.Inventors: John K. Sullivan, Leslie P. Miranda, Colin V. Gegg, Shaw-Fen Sylvia Hu, Edward J. Belouski, Justin K. Murray, Hung Nguyen, Kenneth W. Walker, Taruna Arora, Frederick W. Jacobsen, Yue-Sheng Li, Thomas C. Boone